Synthetic lethality guiding selection of drug combinations in ovarian cancer

201916 citationsJournal Articlegold Open Access

Authors

Andreas Heinzel · Medical University of Vienna

Maximilian Marhold · Medical University of Vienna

P. Mayer · EmergenTec (Austria)

Michael Schwarz · Medical University of Vienna

Erwin Tomasich · Medical University of Vienna

Arno Lukas · EmergenTec (Austria)

Michael Krainer ·

Abstract

A set of drug combinations currently not tested in late stage ovarian cancer clinical trials was identified having impact on synthetic lethal interactions thus being worth of further investigations regarding their therapeutic potential in ovarian cancer.

Topics & Keywords

PARP inhibition in cancer therapy CRISPR and Genetic Engineering RNA and protein synthesis mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PLoS ONE

Volume 14, Issue 1, pp. e0210859-e0210859

DOI: 10.1371/journal.pone.0210859

Field-Weighted Citation Impact: 1.31